Wednesday, July 8, 2026

Patent intelligence · US

US 11865126

Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

granted A61KA61K31/4045A61K31/661A61K31/675
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 100
Patent details — US 11865126
Jurisdiction
US
Status
granted
Grant date
Jan 9, 2024
Expiration
Jan 4, 2044
Claims
30
CPC classes
A61K, A61K31/4045, A61K31/661, A61K31/675
View on Google Patents ↗

Quick answer

US 11865126 (Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin) is held by Compass Pathfinder Limited. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
30
CPC classes
A61K, A61K31/4045, A61K31/661, A61K31/675, A61K9/0053, A61K9/20

More from Compass Pathfinder Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12377112

    Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

    Compass Pathfinder Limited · Expires Jul 31, 2045

    granted
  2. US 12312375

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Expires May 22, 2045

    granted
  3. US 12286483

    Method of treating cancer using CD137 antibodies and PD-1 antagonists

    Compass Therapeutics LLC · Expires Apr 24, 2045

    granted
  4. US 12186285

    Compositions and methods of treatment for tinea pedis

    Compass Therapeutics LLC · Expires Jan 2, 2045

    granted
  5. US 12070594

    Biomedical electrode with anti-microbial properties

    COMPASS HEALTH BRANDS CORP. · Expires Aug 22, 2044

    granted
  6. US 11970538

    Multispecific binding constructs against checkpoint molecules and uses thereof

    Compass Therapeutics LLC · Expires Apr 25, 2044

    granted
  7. US 11939346

    Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

    Compass Pathfinder Limited · Expires Mar 21, 2044

    granted
  8. US 11865179

    Progesterone formulations having a desirable PK profile

    Compass Therapeutics LLC · Expires Jan 4, 2044

    granted

Frequently asked questions

What is US patent 11865126?

US 11865126 (Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin) is held by Compass Pathfinder Limited. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11865126?

Compass Pathfinder Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 100 pharmaceutical patents for this assignee.

When does US 11865126 expire?

Our index shows an expiration date of Jan 4, 2044 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.